Completed PHASE1 INTERVENTIONAL 5-arm NCT06945276

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

A Phase 1 Study to Evaluate Relative Bioavailability and Food Effect of an ALG-097558 Tablet Formulation and the Drug-Drug Interaction Potential of ALG-097558 and Its Metabolite ALG-097730 in Healthy Volunteers

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions COVID-19

Interventions ALG-097558 Dabigatran Itraconazole Placebo

Updated 5 times since 2025 Last updated: Aug 14, 2025 Started: May 13, 2025 Primary completion: Aug 1, 2025 Completion: Aug 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates COVID-19 and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States